EMA Targets Sponsors That Post Trial Results Too Late
Executive Summary
Too many clinical trial sponsors are late in to reporting their study results on the publicly available EU Clinical Trials Register, and the European Medicines Agency is planning to chase up the laggards.
You may also be interested in...
Pharma ‘Doing The Right Thing By Patients,’ Major Trial Transparency Study Finds
Authors of new a study find that while most pharma companies are complying with rules for reporting trial results on the EU Clinical Trials Register, too many trials are still not being reported. They hope their newly launched online EUTrialsTracker tool might help address the situation.
EU CHMP Opinions And MAA Updates
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.
Additional Analyses Help Idorsia Secure English Funding For Chronic Insomnia Drug Quviviq
Quviviq is to become the first dual orexin receptor antagonist available on the National Health Service. Just over 20,000 people in England could receive treatment with the drug in its first year, says the health technology assessment institute, NICE.